Comparison Chart Oramed Pharmaceuticals Inc.
Stocks
ORMP
US68403P2039
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
16:00:00 2026-08-31 EDT
|
5-day change | 1st Jan Change | ||
| 5.020 USD | -0.20% |
|
+4.15% | +76.14% |
| 08-31 | Lifeward Names Josh Hexter as Interim CEO and Rami Aviram as CFO | MT |
| 08-10 | Oramed Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. | Other Biotechnology & Medical Research | -0.20% | +4.15% | +76.14% | +133.49% | -74.49% | 209M |  | | |
- Stock Market
- Stocks
- ORMP Stock
- Charts Oramed Pharmaceuticals Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
